Drug Targets – Products

On July 9th, 2024, the U.S. FDA approved Arcutis Biotherapeutics' ZORYVE® (roflumilast) for treating atopic dermatitis (AD), the most common type of eczema affecting millions in the U.S.

Milestone payment follows successful target identification and validation in separate project under same collaboration.

License agreement provides IRBM access to CRISPR gene editing technology to be applied across its drug discovery services offering.

AMSBIO reports that its extensive range of FDA tissue microarrays reliably enhances tissue cross-reactivity (TCR) and other target validation studies.

CatSci Ltd are thrilled to announce that they have won a Welsh Government SMART Capital Equipment Fund grant to enhance their oligonucleotides capability and offer more and better R&D and manufacturing solutions to customers.

Cresset, announces a collaboration with Enamine to develop innovative new solutions for the early drug discovery process.

Novel GHz-class NMR systems are enabling unprecedented life science and materials research in functional structural biology, drug discovery, metabolomics and cleantech
research.

Download this compendium to learn more about developments in high-throughput screening, target-based drug discovery and fragment-based drug discovery.

Research is like high-stakes poker. The prize? A blockbuster drug. The risk? Billions lost on a dud. Winning comes down to having the best tools to spot the most promising leads.

This app note highlights how reliable kinetics and affinity for high-affinity interactions can be obtained from significantly less data than is commonly used.